-

Drug Farm Doses First Patient in Part 3 of Phase 1 Chronic Hepatitis B Trial

Trial will evaluate DF-006, a first-in-class ALPK1 agonist that stimulates local innate immunity in the liver

GUILFORD, Conn. & SHANGHAI--(BUSINESS WIRE)--Drug Farm, a clinical-stage biopharmaceutical company, announced today that it has dosed the first chronic hepatitis B patient in Part 3 of its Phase 1 clinical trial (ANZCTR Trial ID: ACTRN12621000592842). This trial is evaluating Drug Farm’s first-in-class ALPK1 agonist, DF-006, as a monotherapy and in combination with standard-of-care nucleos(t)side reverse transcriptase inhibitors in treatment-naïve and virologically suppressed patients with chronic hepatitis B infection.

“DF-006 is a first-in-class innate immunity modulator that has demonstrated potent anti-hepatitis B virus (HBV) responses in in vitro and in vivo preclinical studies as described in our recent publication in Hepatology1,” said Drug Farm’s Chief Medical Officer, Dr. Jeysen Yogaratnam. “We will be evaluating DF-006 in various chronic hepatitis B patient subpopulations in our global multicenter placebo-controlled randomized study at sites in Europe and Asia, including China.”

“DF-006 has demonstrated a good safety and tolerability profile to date following single and multiple ascending dose evaluations in healthy volunteers,” said Prof. Ed Gane, the lead Principal Investigator for this study. “As an oral drug administered once weekly, DF-006 has the potential to be the immunomodulator of choice in combination HBV cure regimens”.

  1. Xu C, Fan J, Liu D, Tuerdi A, Chen J, Wei Y, Pan Y, Dang H, Wei X, Yousif AS, Yogaratnam J, Zhou Q, Lichenstein H, Xu T. Alpha-kinase 1 (ALPK1) agonist DF-006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B. Hepatology. 2023 Jan 1;77(1):275-289. doi: 10.1002/hep.32614.

About Drug Farm

Drug Farm is a private biotechnology company developing innovative treatments targeting innate immunity for hepatitis B, heart and kidney diseases, and ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: www.drug-farm.com

Contacts

United States:
Henri Lichenstein, Ph.D.
Chief Executive Officer
hlichens@drug-farm.com

China:
Tony Xu, Ph.D.
Chief Operating Officer
tony.xu@drugfarminc.com

Industry:

Drug Farm

Release Summary
First patient dosed in Drug Farm's part 3 Phase 1 chronic hepatitis B trial.
Release Versions
English

Contacts

United States:
Henri Lichenstein, Ph.D.
Chief Executive Officer
hlichens@drug-farm.com

China:
Tony Xu, Ph.D.
Chief Operating Officer
tony.xu@drugfarminc.com

Social Media Profiles
Drug Farm/Linkedin
More News From Drug Farm

Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting in Denver, CO. The presentation will highlight early evidence of improvements in visual function, optic nerve pathology, and neurological symptoms in patients with ROSAH syndrome, a rare genetic...

Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at IMMUNOLOGY2026, taking place April 15–19, 2026, in Boston, Massachusetts. The presentation will highlight early evidence of clinical benefit and pharmacodynamic improvement in patients with ROSAH syndrome, a rare genetic autoinflammatory disease driven by disease-ca...

Drug Farm Announces U.S. FDA Orphan Drug Designation for DF-003 for the Treatment of ROSAH Syndrome

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DF-003, the company’s investigational small molecule inhibitor targeting ALPK1, for the treatment of patients with ROSAH syndrome, a rare, genetically driven systemic autoinflammatory disease with significant unmet medical need. ROSAH syndrome (Retinal dystrophy, Optic nerve edema, Splenomegaly, Anhidrosis, and Headache) is a progressi...
Back to Newsroom